TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00299507

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: One 0.5 mL sham injection at 6 month intervals
Study: NCT00641537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
Study: NCT03937609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: infliximab iv 5mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: infliximab iv 5mg/kg
Study: NCT01790542

Intervention type: OTHER
Group type: OTHER
Intervention: Iron fortified cereal
Description: Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)

Intervention type: OTHER
Group type: OTHER
Intervention: Iron fortified cereal with fruit

Intervention type: OTHER
Group type: OTHER
Intervention: Meat
Study: NCT04090502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling in hamstring muscle trigger points
Description: Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry needling in hamstring muscle not trigger points
Description: Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
Study: NCT03744052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Messages
Description: Messages regarding physical activity will be texted to participants.
Study: NCT03437655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carie removal
Description: Carie removal with a low speed handpiece

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carie removal
Description: Carie removal with a low speed handpiece
Study: NCT01071629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
Study: NCT02350660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cow's milk
Description: daily consumption of cow's milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: peanut powder
Description: peanut oral immunotherapy
Study: NCT03437655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relative isolation
Description: Relative isolation with cotton and gauze.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relative isolation
Description: Relative isolation with cotton and gauze.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the temporary material based on Zinc Oxide and Eugenol
Description: Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the temporary material based on Mineral trioxide aggregate
Description: Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material insertion on the cavity
Description: Material insertion on the cavity according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material insertion on the cavity
Description: Material insertion on the cavity according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Finishing the temporary direct restoration
Description: Excess cement removal; Occlusal Adjustment; Finishing and polishing.
Study: NCT01071629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
Study: NCT02338375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cartistem
Description: Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cartistem
Description: Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
Study: NCT05545644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family-Involved Treatment for Alcohol Use Disorder
Description: Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Family-Involved Treatment for Alcohol Use Disorder
Description: Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
Study: NCT03437655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Finishing the temporary direct restoration
Description: Excess cement removal; Occlusal Adjustment; Finishing and polishing.
Study: NCT00909909

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam boost
Description: 3-dimensional conformal radiation therapy and intensity modulated radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam boost
Description: 3-dimensional conformal radiation therapy and intensity modulated radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Description: accelerated, hypofractionated whole breast irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Description: accelerated, hypofractionated whole breast irradiation
Study: NCT03985397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discharge training
Description: Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
Study: NCT05659342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA Technique
Description: the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Lumbar Traction
Description: Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises
Study: NCT00786188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brisdelle (paroxetine mesylate)
Description: Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Subjects will receive a sugar pill.
Study: NCT03791190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Description: Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No-anticoagulation
Description: Patients accepted CRRT without anticoagulant.
Study: NCT02142881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication intensification
Description: Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Antihypertensive medications will be adjusted by the participants' providers (usual care).
Study: NCT01643109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casting & CIMT
Description: A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies.
Study: NCT02612558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 150 mg bid
Description: Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
Study: NCT01960972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salt substitute
Description: A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
Study: NCT04214457

Intervention type: PROCEDURE
Intervention: Biopsy and peripheral blood collection
Description: After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record.
Study: NCT02444195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery With Audio Media
Description: Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
Study: NCT02924051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cooking skills and nutritional education
Description: Participants in this group will develop an understanding of healthy food options and healthy food preparation.
Study: NCT05441293

Intervention type: PROCEDURE
Intervention: flap reconstruction
Description: received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities

Intervention type: PROCEDURE
Intervention: flap reconstruction
Description: received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
Study: NCT03234010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21092
Description: An electronic cigarette
Study: NCT04957030

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ULDCT group
Description: underwent ultralow-dose chest CT
Study: NCT03122977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FM-SRP
Description: Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.
Study: NCT01015469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic Roux-en-Y gastric bypass
Description: Conventional laparoscopic Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
Description: conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
Study: NCT02934191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
Study: NCT06550713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3455 tablet+Azacitidine for Injection
Description: TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.
Study: NCT04505254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT03431545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PALS and
Description: Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEECH
Description: Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
Study: NCT02952586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab + SOC Chemoradiation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chemoradiation
Description: Cisplatin + Radiation Therapy
Study: NCT01425658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
Study: NCT02986477

Intervention type: OTHER
Group type: OTHER
Intervention: Contrast Ultrasound
Description: For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
Study: NCT03234010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21093
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21096
Description: An electronic cigarette
Study: NCT02470845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herbal patches of Tian Jiu group
Description: The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm\*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo patches of placebo-control group
Description: The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
Study: NCT02786225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Care- Usual Care + primary midwife
Description: Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
Study: NCT01577550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (very high i.v. dose)
Description: Single very high i.v. dose BI 655066
Study: NCT02861911

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Current flow between sensory and motor threshold
Description: Artificial strength training by means of neuromuscular electrical stimulation (NMES)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current intensity upper of motor threshold by Kneehab XP technology
Description: Artificial strength training by means of neuromuscular electrical stimulation (NMES)